All In Biotech

Drug Trial Radar · NCT01447043

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

AURA Study: A Retrospective Non-interventional Study (NIS) to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (wAMD)

Last checked: Nov 20, 2026Latest source record: Jan 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,609

Actual

Start

Jan 2009

Primary completion

Aug 2011

Study completion Nov 2012

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 5, 2011

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

Conditions

  • Ophthalmology, Macular Degeneration

Interventions

  • RanibizumabDrug

    Patients with wet AMD treated with ranibizumab as prescribed by physician

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in visual acuity after start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chardTime frame: Baseline and 24 months

Locations

10 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Many Locations, Australia

  • Site not named

    Many Locations, Canada

  • Site not named

    Many Locations, France

  • Site not named

    Many Locations, Germany

  • Site not named

    Many Locations, Ireland

  • Site not named

    Many Locations, Italy

  • Site not named

    Many Locations, Japan

  • Site not named

    Many Locations, Netherlands

  • Site not named

    Many Locations, United Kingdom

  • Site not named

    Many Locations, Venezuela

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.